Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines

Epigeneticists may be looking for epigenome-disease associations in the wrong place

For a decade, thousands of PhDs in epigenetics may have been relying on the wrong tool as they study the biological processes that regulate how and when genes are expressed or silenced.

January 27, 2023

Vol.49 No.04

By Jacquelyn Cobb and Matthew Bin Han Ong

Conversation with The Cancer Letter

Baylor’s Waterland & Coarfa: We see CoRSIVs as the new standard in epigenetic epidemiology

It took a team of researchers more than 18 months to get their paper on epigenetic variation published—likely because they are saying that epigeneticists have been fishing in the wrong pond for a decade.

January 27, 2023

Vol.49 No.04

By Jacquelyn Cobb and Matthew Bin Han Ong

Guest Editorial

NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research

As members of the 118th Congress returned to Washington this week, everyone is focused on raising the nation’s debt limit, especially following Treasury Secretary Jane Yellen’s announcement that her agency would begin taking extraordinary measures to prevent the government from triggering a default.

January 27, 2023

Vol.49 No.04

By Lisa M. Coussens

Clinical Trials & Tribulations

Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization”

The release of FDA’s draft guidance, “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases,” has been greatly anticipated since June 2021, when FDA announced in its accelerated approval of the KRASG12C inhibitor sotorasib that it would require a randomized, controlled trial comparing the efficacy of the labeled dose (960 mg once daily) to a 75% lower dose (240 mg once daily) as a condition of full regulatory approval (The Cancer Letter, June 11, 2021; April 29, 2022).

January 27, 2023

Vol.49 No.04

By Mark J. Ratain and Garth W. Strohbehn

Cancer History Project Conversation with The Cancer Letter

Jim Allison believed in the power of T cells—when hardly anyone else did

Throughout Jim Allison’s early career, the field of oncology appeared to be unfazed by his T cell research. Allison’s introduction to the now-famed immune cell came in an undergraduate immunology course, where even the professor was apprehensive about Allison’s fascination with the recently discovered T cells. “I remember going to see the professor after class...

January 27, 2023

Vol.49 No.04

By Alexandria Carolan

In the Archives

Duke marks 50 years of gynecologic care; celebrates legacies of oncology doctors and nurses

Duke Cancer Institute is commemorating 50 years of gynecologic care and research.

January 27, 2023

Vol.49 No.04

Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines

YOU MAY BE INTERESTED IN

Epigeneticists may be looking for epigenome-disease associations in the wrong place

Baylor’s Waterland & Coarfa: We see CoRSIVs as the new standard in epigenetic epidemiology

NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research

Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization”

Jim Allison believed in the power of T cells—when hardly anyone else did

Duke marks 50 years of gynecologic care; celebrates legacies of oncology doctors and nurses

Renew today!

Subscriber content

Login